For this prospective , multicenter , randomized , double-blind and placebo-controlled trial , a total of 300 HFMD outpatients from 3 class 3A hospitals from July 2011 to June 2013 were divided into treatment ( ribavirin aerosol ) and control ( placebo ) groups ( n = 150 each ) .